Association of haemoglobin levels in the first trimester and at 26-30 weeks with fetal and neonatal outcomes: a secondary analysis of the Global Network for Women's and Children's Health's ASPIRIN Trial.
S JessaniSarah SaleemM K HoffmanS S GoudarR J DermanJ L MooreA GarcesL FigueroaN F KrebsJ OkitawutshuA TshefuC L BoseM MwenechanyaE ChombaW A CarloP K DasArchana B PatelP L HibberdF EsamaiE A LiechtyS BucherT L NolenM Koso-ThomasM MiodovnikElizabeth M McClureR L GoldenbergPublished in: BJOG : an international journal of obstetrics and gynaecology (2021)
Both lower and some higher haemoglobin concentrations were associated with adverse fetal and neonatal outcomes at 6-13 weeks and 26-30 weeks of gestation.
Keyphrases
- gestational age
- public health
- healthcare
- low dose
- clinical trial
- preterm infants
- young adults
- polycystic ovary syndrome
- preterm birth
- cardiovascular events
- phase iii
- cardiovascular disease
- metabolic syndrome
- phase ii
- health information
- risk assessment
- pregnancy outcomes
- pregnant women
- health promotion
- climate change
- adverse drug
- double blind